FDA Approves Mayne’s Halobetasol Foam For Adolescents

Australian Company Strengthens Its Dermatology Portfolio With US Lexette Nod

23 Sep 2021

• By Akriti Seth

Mayne Pharma has announced receiving US FDA approval for its Lexette (halobetasol propionate) 0.05% foam for the treatment of plaque psoriasis for use in adolescents. With Lexette, Mayne now markets more than twenty dermatology products in the US including four branded products.

Dermatology — Mayne Pharma markets more than twenty dermatology products in the US • Source: Alamy

Australia-based Mayne Pharma USA has received US Food and Drug Administration approval for its Lexette (halobetasol propionate) 0.05% foam, “a super potent topical corticosteroid” for the treatment of plaque psoriasis for use in adolescents.

Commenting on the development, Mayne Pharma’s CEO Scott Richards said, “Lexette has been shown to be a safe and effective...